We are live on ! Find out more
PALI icon

Palisade Bio
PALI

10 hedge funds and large institutions have $388K invested in Palisade Bio in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

12% more capital invested

Capital invested by funds: $347K → $388K (+$40.3K)

11% more funds holding

Funds holding: 9 → 10 (+1)

0.19% more ownership

Funds ownership: 8.29% → 8.48% (+0.19%)

Holders
10
Holders Change
+1
Holders Change %
+11.11%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
+$184K
2
AC
Armistice Capital
New York
+$140K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$26.5K
4
UBS Group
UBS Group
Switzerland
+$23.5K
5
TRCT
Tower Research Capital (TRC)
New York
+$8.13K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$29.1K
2
Morgan Stanley
Morgan Stanley
New York
-$350

PALI Hedge Fund Activity: Q4 2024 in Review

10 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2024, worth a combined $388K — up 12% from $347K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new PALI positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Cetera Investment Advisers, opening a new position worth an estimated $184K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $29.1K sold.

  • 10 institutional investors held Palisade Bio (PALI) as of Q4 2024, up from 9 in Q3 2024.
  • Funds reported $388K of Palisade Bio stock for Q4 2024, up 12% quarter-over-quarter.
  • 2 funds opened new Palisade Bio positions in Q4 2024 and 1 closed out, a net change of +1 holder.
  • The largest Palisade Bio buyer in Q4 2024 was Cetera Investment Advisers, an estimated $184K added.
  • The largest Palisade Bio seller in Q4 2024 was JP Morgan Chase, an estimated $29.1K sold.

Based on aggregated 13F filings for Q4 2024.